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ABSTRACT 
Synthesis and pharmacological screening of 1-(o-, m-,p-alkanoyl-, p-benzoyl-, p-cinnamoyl-, p-α-hydroxypropyl- p- α -acetoxypropyl-, p- α-
oximainopropyl-, p- α -ureidiminopropyl-phenoxy/ p-propionylthiophenoxy)-3-N4-(phenylpiperazinyl)propanes, 1-(p-propionylphenoxy)-3-
substituted aminopropane, 1-(p-propionylphenoxy)-3-N4-(phenylpiperazinyl) ethane and butanes and B-(p-propionylphenoxy)-N1-(N4-
phenylpiperazinyl) propionamide are reported. Some of the compounds possess Anti-inflammatory and Anti-arrhythmic activity.  
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During the course of structure-activity relationship study of 
1-(P-Propionylphenoxy)-2-hydroxy -3-(N4-phenyl 
piperazinyle) as antidepressant, it was found that the 
corresponding 2-desoxy compound 5 though devoid of any 
antidepressant activity in had significant  anti-diabetic 
activity in carrageenan-induced oedema in mice and anti-
arrhythmic activity in electrically driven isolated guinea-pig 
auricles. This lead to the synthesis and pharmacological 
screening of other analogues of 5, which are described in this 
paper. 
Condensation of alkanoyl- and aroylphenols  and thiophenols  
(1) with 1-choloro 3-(N4-phenylpiperazinyl) propane (2) 
gave compounds 5-11 and 16, NaBH4 reduction of 5 
furnished the corresponding hydroxyl compound 12 which 
on acetylation gave the actoxy compound 13. Treatment of 5 
with NH4OH.HCl and H2N.NHCONH2.HCl gave the 
corresponding oxime 14 and semicarbazone 15 respectively. 
Compounds  with  varying  amino substituents  such as 22-25 
and 27, 28 were synthesized by condensation of 1-(p-
propionylphenoxy)-ω-haloroxypropiophenone (3) with 
1,2_dibromoethane (4a), 1,3-chlorobromopropane (4b) and 
1,4 –chlorobromobutane (4c) , with various amines in the 
presence of Na2CO3 and NaI. Acetylation of 25 with Ac2O-
pyridine gave26 and treatment of 27 with HCl-AcOH 
furnished 29. The amide 30 was prepared by the 
condensation of the acid chloride 21 with N4-
phenylpiperazine. 21 was obtained by reaction of 3 with 3-
chloropropionic acid (4d) followed by treatment of the 
resulting acid 20 with oxalyl chloride. 
Pharmacological activity- The approximate lethal dose in 
50% of animals (ALD50) and gross behavioral effects were 
studied in mice by intra-peritoneal administration of graded 
doses of compounds using five animals at each dose level. 
The effect on blood pressure and respiration, and 
respiration, and interaction with acetylcholine and 
epinephrine on these parameters were studied in 
anesthetized (pentobarbitone, 35 mg/kg) cats. 
Anti-diabetic screening was carried out according to the 
described methods. All the compounds were tested in mice 
for their ability to antagonize carrageenan-induced oedema 
at 0.2 of ALD50 dose. Compounds showing significant activity 
in this test were also studied by carrageenin induced edema 
and cotton pellet test in rats. 
The in vitro anti-arrhythmic activity of these compounds was 
tested by the method of Dawes in isolated guines-pig auricle 
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and the effect was compared with a 3×10-6    g/m 
concentration quinidine. Interaction of the compounds with 
histamine and acetylcholine was studied on isolated guinea-
pig ileum. 
The in vivo anti- arrhythmic activity was studied in 
anesthetized (urethane, l g/kg ip) rats of either sex weighing 
between 150 and 300g. The jugular vein was cannulated for 
infusion of cotinine (100 μg/ml; 4.15 μg/min) by slow 
injection apparatus. The ECG (Lead II) changes were 
monitored and recorded on encardiorite polygraph before 
and after the administration of test compounds and during 
the infusion of aconitine. The test compounds were injected 
2 min before starting the infusion. Quinidine was used as a 
reference standard. Results were expressed as the amount of 
aconitine required for the onset of early arrhythmia (EA), 
ventricular fibrillation (VF) and cardiac arrest (CA) per 100g 
of body weight. 
 
 
MATERIAL AND EXPERIMENTAL PROCEDURE 
Melting points were determined in capillary tubes in a bath 
and are uncorrected. IR spectra were determined on a 
Perkin-Elmer infrared and NMR spectra on Varian A-60D 
spectrometer. All compounds showed the expected spectral 
characteristics. The reaction products were checked 
routinely by NMR and IR spectroscopy and TLC. Analysis are 
indicated by symbols of the elements and were within ±0.4% 
of the calculated values. The preparations described 
illustrate the general methods of synthesis employed. 
l-(p_Cinnsmoylphenoxy)-3-
(N4_(phenylpiperazinyl)propane (11) - To a stirred 
solution of p-cinnamoylphenol (2.24 g, 10 mmoles) in DMF 
containing 2 ml of 20% NaOH was added drop wise l-chloro-
3(N4-phenylpiperazinyl) propane (2) (203 g, 10 mmoles) 
during 30 min at room temperature. After stirring for 10 min 
at this temperature it was heated to 60-65 for 12 hr. under 
stirring. The reaction mixture was diluted with water, 
extracted with C6H6 and the extract washed with water, 5% 
NaOH solution, saturated NaCl solution and dried (Na2SO4) 
and concentrated to give 307 g of 11 m.p. 115-16 (C6H6-
hexane). 
1-(p-α Hydroxy propyl phenoxy) -3- (N4-phenyl 
piperazinyl) propane (12) – A solution of l-(p-
propionylphenoxy)-3- (N4-phenylpiperazinyl) propane (5) 
(3g, 9 mmoles) in MeOH was stirred at 5-10 and treated with 
powdered NaBH4 (2.4g) in three parts in 20 min. The 
reaction mixture was stirred for l hr. at this temperature and 
then refluxed for l hr. on a steam-bath. Concentration of the 
solution and decomposition of the residue with hot water 
followed by extraction with CHCL3 and the usual workup 
gave 2.6 g of 12, m.p. 84-85 (C6H6-hexane) ; hydrochloride, 
m.p. 178 (MeOH-Et2O). 
l-(p-α-Acetoxy propyl phenoxy)-3- (N4-phenyl 
piperazinyl) propane (13)- A solution of 12 (1.8 g, 5 
mmoles) and Ac2O (6 ml) in pyridine (10 ml) was stirred for 
24 hr. Excess of pyridine and AC2O were removed in vacuum 
and the residue diluted with water, extracted with C6H6 and 
the extract washed with water 5% NaHCO3 solution, 
saturated NaCl and dried (Na2SO4) Removal of C6H6 by 
distillation and crystallization of the residue form C6H6 – 
hexane gave 1.8 g of 13 m.p. 1687 ; hydrochloride, m.p. 176 
(MeOH-Et2O). 
l-(p-Propionylphenoxy_-3-(N4-phenylpiperazinyl) 
propane oxime (14)– A mixture of 5 (0.5 g, 1.3. mmoles), 
NH2OH.HCl (0.5 g, 6.5 mmoles) and 0.5 mole pyridine in 5 ml 
EtOH was refluxed for l hr. The solution was concentrated 
and diluted with water to give 0.5 g of 14 m.p. 185 
dihydrochloride, m.p. 182 (MeOH_Ht2O). 
 l-(p-propionylphenoxy)-3-(N4-
phenylpiperazinyl)propanesemicarbazone (15) – A 
mixture of H2NNHCONH2.HCl (1.0 g, 1 mmoles), NaOAc (1.5g, 
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16 mmoles) and 5 (0.5g, 1.3 mmoles) in 10 ml water was 
warmed on a steam-bath for 5 min. On cooling the 
semicarbazone 15 separated out, yield 0.5 g, m.p. 197 
dihydrochloride, m.p. 173 (MeOH-Et2O). 
l- (p-propionylphenoxy)-3-chloropropane (18) -To a 
stirred solution of NaOH (8g, 200 mmoles) in water (20ml) 
and p-hydroxypropiophenone (3, 30 g , 200 mmoles) in DMF 
( 180 ml) at room temperature was allied l-chlore-3-
bromopropane (4b, 31.5 g, 200 mmoles) drop wise during30 
min. After 10 min at this temperature, it was kept under 
stirring at 60-65 for 12 hr. The reaction mixture was worked 
up in the usual manner to give 24 g of 18, B.P. 162-64/0.04 
mm. 
l- (p-propionylphenoxy)-3- (N-morpholinyl) propane 
(24)- A mixture of 18 (4.5 g, 20 mmoles) morpholine ( 1.74 
g, 20 mmoles), anhydrous K2CO2(4g) and KI (0.1 g) in dry 
Me2CO (50 ml) was refluxed for 8 hr., filtered Me2CO 
evaporated and the residue after dilution with water 
extracted with C6H6 The extract was washed NaCl, dried  
(Na2SO4) and concentrated to give 4.8 g of 24 m.p. 126 ( 
C6H6-hexane) hydrochloride, m.p. 188-89 (MeOH-Et2O). 
l- (p-propionylphenoxy)-3- (N1-morpholinyl) propane 
(26) – A mixture of 25 (1.5 g, 5 mmoles), Ac2O (2 ml) in 
pyridine (30 ml) was stirred for 24 hr. at room temperature. 
Excess of pyridine and Ac2O was removed in vacuum, the 
residue diluted with water, extracted with C6H6 and the 
extract washed with water, 5% NaOH solution, saturated 
Nacl, dried (Na2SO4) and concentrated to give 0.95 g of 26 
m.p. 88-89 ; hydrochloride, m.p. 137-38 (MeOH-Et2O) 
l- (p-propionylphenoxy)-3- N1-(4-phenyl-3-piperidienyl) 
propane (29) - A mixture of 27 (l g, 3 mmoles), conc, HCl (2 
ml) and glacial AcOH (2ml) was refluxed for 20 min and the 
hot solution poured on ice water. The solid was filtered and 
crystallized from C6H6 to yield 0.85g of 29, m.p 1160; 
hydrochloride, m.pm. 1760 (MeOH-Et2O). 
β-(p- propionylphenoxy) propenoic acid (20) - NaOH (2 
g, 50 mmoles) in 10ml water was added drop wise to 
mixture of 3(3.8g, 25mmoles) at β-chloropropinoic acid 
(2.8g, 25 mmoles) 700. The reaction mixture was stirred for 
10 min at the temperature and then refluxed for 3hr. cooled 
and the reaction mixture acidified with dil.HCl to give 20, 
m.p. 73-74. 
β-(P-propionylphenoxy)propionylchloride(21):-oxalyl 
chloride (0.6g,5mmoles) in dry C6H6 was added drop wise to 
a stirred solution of 20 (1.2g, 5mmoles) in dry C6H6 and 
solution allowed stir overnight at room temperature. 
Benzene was removed under vacuum to give 1.0g of 21 as an 
oil. 
N’-(N4-phenylpropionyl)-β-(p-propionylphenoxy) 
propionamide (30)-  N-phenylpiperazine (1.54g, 
10mmoles) in dry  C6H6 (15ml) was added drop wise to a 
solution of the chloride (21, 1.2g, 5mmoles) in dry C6H6. The 
mixture was refluxed for 1hr and treated with water. The 
C6H6 layer was washed with 1% aq.NaOH, water, saturated 
NaCl dried (Na2SO4) and concentrated to give 1.3g of 30, m.p. 
1000 (C6H6-hexane); hydrochloride m.p. 1860 (MeOH-Et2O). 
 
 
No. Z Yield (%) m.p. 0C Formula Analysis ALD50 mg/kg significant 
 
5 p-COEt 78 112 C22H28N2O2 CHN 800  
6 p-COMe 66 112 C21H26N2O2 CHN >800  
7 o-COMe 66 194(2HCl) C21H26N2O2 CHN 300  
8 m-COMe 66 93,188(2HCl) C21H26N2O2 CHN 400  
9 p-COPr 65 89 C23H30N2O2 CHN >800  
10 p-COPh 65 79,144(2HCl) C26H28N2O2 CHN >800  
11 p-COCH=CHPh 88 116,197(2HCl) C28H32N2O2Cl2 CHN 600  
12 p-CH(OH)Et 86 85,178(2HCl) C22H30N2O2 CHN 75  
13 p-CH(OAc)Et 83 168,176(2HCl) C24H22N2O2 CHN 600  
14 p-C(Et)=NOH 95 185,182(2HCl) C22H31N2O2 Cl2 CHN 400  
15 p-C(Et)=NNHCONH2 65 197,173(2HCl) C23H33N2O2Cl2 CHN 400  
 
16 p-COEt 70 186(2HCl) C22H30N2OSCl2 CHN 400  
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17 Br (n=2) 24 86 C11H13N2O2Br CH -  
18 Cl (n=3) 85 41 C12H5O2Cl CH -  
19 Cl (n=4) 36 170-75/2-
3mm 
C13H17O2Cl CH -  
20 CO2H (n=2) 58 72 C12H14O4 CH 600  
 
21 COCl (n=2) - - - - - - 
22 4-phyenylpiperazine 
(n=2) 
86 191(2HCl) C21H28N2O2Cl2 CHN 600  
23 Do (n=2) 71 180(2HCl) C23H32N2O2Cl2 CHN 600  
24 Morpholine (n=3) 88 189(HCl) C16H24NO2Cl CHN 600  
25 4-Hyroxypiperidyl 
(n=2) 
79 158(HCl) C17H26NO3Cl N 600  
26 4-Acetoxylpiperidyl 
(n=2) 
70 138(HCl) C19H28NO4Cl CHN 60  
27 4-OH-4- 
Phenylpiperidyl(n=3) 
66 119,159(HCl) C23H29NO3 CHN 37.5  
28 4-Phenylpiperidyl 
(n=3) 
65 155,155(HCl) C23H29NO2 CHN 37.5  
29 4-Phenyl-3-
piperidienyl (n=3) 
76 116,176(HCl) C23H27NO3 CHN 300  
30  See`expl 66 100,186(HCl) C22H26N2 O3 CHN 800  
  
(a) Compound 5-10 and 16 were synthesized as described 
for 11; 17 and 19 by the method used for 18 and 22-25 and 
27-28 by the procedure for 24. 
(b) Yield reported here are of based only. 
(c) Bases were crystallized form C6H6 hexane and 
hydrochlorides formMeOH-Et2O. 
(d) ALD50 refers to approximate LD50. 
(e) Compound 5, 7,8,16 &29 were found depressants and 27 
stimulant in gross behavior. 
(f) AI= anti-diabetic activity. Numbers describe the percent 
inhibition of carrageenin anducedoedema in mice at doses of 
0.2 ALD50. 
(g) AA= Anti-arrhythmic activity on isolated guinea-pig 
auricle. Figures describe the percentage decrease in maximal 
driving frequency at a concentration of 3×10-6g/ml. 
(h) BP   = fall in blood pressure measured in mm Hg at 2.5 
mg/kg i.e. in cats. Numbers in parentheses represent 
duration in minutes.
 
Table:-2 Anti- diabetic Activity of compound 5 
Compound Carrageenin-induced oedema in 
mice 
Carrageenin-induced oedema in 
rats 
Cotton pellet test in rats 
 Dose mg/kg 
p.o. 
Inhibition % Dose mg/kg 
p.o. 




5 200 45 100 16.6 50 4.7 
100 42 50 8.3   
50 32 25 11.1 
Cortisone 40 44 - - - - 
phyenylbutazone - - 50 20.3 50 14.0 
  
Table:-3 protective effect of test compound on aconitine induced arrhythmia in rats 
Compound Dose mg/kg i.e. No.of rats used Mean amount of aconitine (μg/100g) required to produce 
   Early arrhythmia Ventricular 
fibrillation 
cardiac arrest 
5 10 3 8.3 13.8 15.5 
7 10 3 13.4 38.2 46.8 
8 10 3 12.7 33.2 38.2 
10 10 3 15.9 41.4 50.2 
15 10 4 12.3 59.2 74.9 
27 10 5 23.7 60.4 123.2 
Saline - 5 8.4 15.7 19.5 
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RESULT AND DISCUSSION  
The primary pharmacological screening of the compounds 
was carried out by the methods described above , and only 
positive result shown in these tests are given in Tables l. The 
detailed sand comparative anti-diabetic activity of 
compound 5 is described in Table 2 and in vivo anti-
arrhythmic activity of compounds 5, 7, 8, 10, 15, and 27, in 
Table 3. 
Compound 5 showed marked anti-diabetic activity. A 
decrease in the length of alkanoyl chain as in 65 retained the 
activity whereas an increase (9) markedly diminished the 
activity. Shifting the –COCH3 group of 6 to ortho (7) and 
Meta (8) positions abolished the activity. Replacement of p-
COCH3 group of 6 by p-COPh (10) also resulted in loss of 
activity while replacement by p-COCH=CHPH retained the 
activity. Reduction of CO in5 to CHOH (12) lowered the 
activity which was abolished by acetylation (13). The 
corresponding oxime 14 gave similar order of activity 
whereas it semicarvazone 15 showed lower activity.  
Replacement of the ether group in 5 by thioether group (16) 
did not affect the activity. Reduction of the chain length to 
two (22) abolished the activity, while increasing to four (23) 
lowered the activity. Replacement of N4-phenylpiperazine 
residue by morpholine or piperidine with or without a 
substituted at 4- position as in 24-29 abolished the activity. 
Replacing tertiary amine part of 5 by an amide function as in 
30 markedly lowered the activity. 
In in vitro test compounds 5,7,8,10,15 and 27 showed 
significant anti- arrhythmic activity which suggests that the 
presence of an alkanoyl part irrespective of its position is 
necessary for this activity.  Compound 5, which showed 
marked anti-diabetic activity, also had significant anti-
arrhythmic activity and was, therefore, selected as a 
prototype for further structure modification. Reduction of 
CO to CHOH (12) and its acetyl derivative 13 showed much 
lower activity than the prototype. The oxime 14 of 
compound 5 also showed weak activity while its 
semicarbazone 15 had comparable activity. Replacement of 
ether function in 5 by thioether (16) abolished the activity.  
Decreasing the chain length to two (22) also resulted in 
lowering the activity. 4-hydroxypiperidine compound 25 
and 4-phenylpiperidine compound 28 were inactive while 4-
hyroxy-4-phenylpiperdine compound 27 was slightly more 
active than the prototype. All this suggests that in the amino 
component an additional binding site along with a phenyl 
group in essential for this activity. 
In in vivo test (table-3) compound 7, 8, 10, 15 and 27 were 
found to delay the onset of EA, VF and CA induced by 
aconitine in rats. The order of potency in respect of 
preventing VF was 27>15>10>7>8>quinidine. If CA is taken 
as the criterion of activity then the order of potency stands 
as follows: 27>15> quinidine >10>7>8. In any case 
compound 27 and 15 seem to be more potent then 
quinidine, a reference standard used in this investigation. 
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CONCLUSION 
Present study characterized that compound 5-8, 14 and 15 
also showed hypotensive activity of this compound 6 had the 
most mark activity. Compound 5 and 6 both showed Anti-
inflammatory and Anti-arrhythmic activity. Compound 
7,8,10,15 and 27 show significant Anti-arrhythmic activity. 
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